Movement Alert｜WUXI BIO falls 3.79% in Regular Trading, UBS downgrade to neutral weighs on sentiment

Market Focus10-27

On October 27, WUXI BIO fell 3.79% in Regular Trading, trading at HK$43.98, with turnover of HK$215 million.

The move was associated with a recent broker action: UBS downgraded the company to neutral and set a target price of RMB27, which became the most direct catalyst for renewed pressure on the shares.

Background disclosures were comparatively solid. The company previously reported interim revenue of RMB11.787 billion and adjusted net profit of RMB3.937 billion, while its Wuxi Mashan site passed an unannounced US FDA GMP inspection with no major or critical findings. Even so, the rating cut appears to have outweighed those positives in the near term, and related names including WUXI APPTEC and WUXI XDC were also weaker.

The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment